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Introduction
Aromatase activity in peripheral tissues including the
breast is the main source of estrogen in postmenopausal
women. There is evidence that local estrogen synthesis by
breast aromatase contributes to mammary carcinogenesis.
Therefore, we have postulated that high breast weight is
associated with ER+ tumours.
Patients and methods
The mastectomy specimen weight, ER and PgR status for
62 consecutive patients who had a total mastectomy for
operable breast cancer were retrospectively reviewed. The
ER/PgR positivity was assessed using immunohistochem-
istry (Quickscore system 0–8) by a breast pathologist. ER/
PgR status was considered positive if the score was 4 – 8.
Results
Overall the breast weight was higher in patients with ER+
disease. The weight was found to be significantly higher in
women aged 50 years or older with ER+ tumours (669 vs.
220 grams, p = 0.015). There was no significant difference
in breast weight between ER+ and ER- tumours in women
aged less than 50 years (median weight: 440 vs.408 grams,
p = 0.379). We observed a non-significant association
between higher breast weight and PgR positivity (809 vs.
510 grams, p = 0.084) and absence of c-erb B2 (p =
0.088).
Conclusion
In women aged 50 years or older with breast cancer, high
breast weight is significantly associated with ER+ tumours.
If this is confirmed in larger prospective studies, our find-
ings may have implications regarding breast cancer pre-
vention with anti-estrogens.
Introduction
Breast cancer remains the most common cancer in
females. It has been estimated that one in eight women
will develop breast cancer during their lifetime in the USA
[1]
Approximately two thirds of postmenopausal breast can-
cer patients have hormone dependent breast cancer that
requires estrogen for tumour growth. It is well established
that estrogens enhance growth and proliferation of certain
target cells such as breast epithelial cells and estrogen
dependent mammary carcinoma cells [2].
In postmenopausal women, estradiol does not appear to
function as a circulating hormone; it is biosynthesized
from androgens by the cytochrome P450 enzyme com-
plex called aromatase [3] which is a product of the CYP19
gene, with the highest levels of this enzyme present in the
peripheral adipose tissues of postmenopausal women [3].
Estrogen acts mainly at a local level as a paracrine or intra-
crine factor.
Aromatase has been found and measured in the stromal
cell component of the normal breast as well as the breast
tumour. Also, the enzyme has been detected in the breast
epithelial cells in vitro [4-8]. Furthermore, expression of
aromatase is highest in or near breast tumour sites
[5,6,9,10]. It has been observed that the aromatase activity
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and expression is highest in the breast quadrant contain-
ing the tumour, such expression in the tumour containing
quadrant is equal to that in the tumour itself, but double
that in a quadrant of the same breast which does not con-
tain a tumour which in turn is double the expression in
the cancer free breast [10].
Evidence that postmenopausal obesity and weight gain
are positively associated with postmenopausal breast can-
cer risk has been substantiated especially in women who
never used hormone replacement therapy [11].
The aim of this study was to examine the hypothesis ques-
tioning the relationship between oestrogen and progester-
one receptor status and breast tissue weight in
postmenopausal women who had mastectomy for opera-
ble breast cancer.
Patients and methods
The mastectomy specimen weight, estrogen receptor (ER)
and progesterone receptor (PgR) status for 62 consecutive
patients who had a total mastectomy for operable breast
cancer were retrospectively reviewed. Breast specimen
weight was obtained from the pathology laboratory
reports in grams. ER and PgR status was determined by
immunohistochemistry (IHC) using the Quickscore sys-
tem by a breast pathologist. ER/PgR status was considered
positive if the score was 4 – 8. We also examined other
parameters including tumour size, grade, nodal status, c-
erb B2 expression and patient's age.
Correlation between breast weight and receptor status was
examined in two groups of patients according to their age,
50 years and older and younger than 50 years.
Results
59 patients had invasive breast cancer and 3 patients had
ductal carcinoma in situ (DCIS). Estrogen receptors were
positive (ER+) in 50 patients (Quickscore: 4–8) and nega-
tive (ER-) in 12 patients (Quickscore: 0)
In general, breast weight was higher in patients with ER+
disease; median weight was 570 grams in ER+ patients
compared to 413 grams in ER- patients (p = 0.04)
Patients were divided into two groups according to age.
The first group consisted of patient aged 50 years and over
(n = 43) with a median age of 60 years (range 51–83) and
the second group contained those patients aged less than
50 years (n = 19) with a median age of 42 years (range 29–
48).
Within the first group, breast weight was found to be sig-
nificantly higher in women with ER+ tumours (669 vs.
220 grams, p = 0.015). Figure (1) demonstrates the rela-
tionship between the mastectomy specimen weight and
ER status in the first group. Furthermore, when ER- and
PgR – tumours were considered together the association
was stronger (p = 0.003). On the other hand, there was no
significant difference in breast weight between ER+ and
ER- tumours in women in the second group (median
weight: 440 vs.408 grams, p = 0.379).
There was no significant difference in tumour's size
between ER+ and ER- patients. Furthermore, the tumour's
grade was higher in ER- patients (p = 0.009) and patient's
age had no significant impact on the receptor status.
We observed a non-significant association between higher
breast weight and PgR positivity (809 vs. 510 grams, p =
0.084) and absence of c-erb B2 (p = 0.088).
Finally, there was no association between breast weight
and nodal status or tumour's grade.
Discussion
It has been established that obesity and weight gain are
risk factors of breast cancer in postmenopausal women
[12]. This relationship is explained by the fact that
increased body weight is due to increased amount of adi-
pose tissue in the body including breasts and subse-
quently increased of aromatase activity, thus increasing
the local production of estrogen by aromatization of cir-
culating androgens [13-16]. This process is a very
ER status and mastectomy weight Figure 1
ER status and mastectomy weight. (Age = or > 50 
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important growth stimulating system in hormone
dependent breast cancer [17].
Breast tissue and particularly the breast adipose tissue in
postmenopausal women with breast cancer seem to have
an increased aromatase expression. Agrawel et al studied
9 women undergoing breast reduction mammoplasty and
18 breast cancer patients undergoing mastectomies. Non-
tumour bearing adipose samples from mastectomies
expressed significantly more aromatase than adipose tis-
sue taken from mammoplasty patients, a difference that is
unlikely to be due the tumour's influence on aromatase
expression [10].
The relationship between a higher body mass index (BMI)
and the risk of ER+/PgR+ breast cancer has been studied
previously [18-23]. In a case control study by Shelley et al
a significantly increased risk of ER+/PgR+ breast cancer
with increasing body size was observed. On contrast,
other studies showed a greater frequency of ER- breast
cancer among obese women [24-27].
The relationship between increased breast weight in post-
menopausal women and receptor status has not been pre-
viously examined. In our study we hypothesised that in
breast cancer patients; ER+ breast cancer was associated
with a higher breast weight than ER- disease. This hypoth-
esis was proved to be correct in postmenopausal women.
Furthermore, such an association was not observed in
women aged less than 50 years.
Our study has several limitations; firstly, we did not
include other risk factors such as body mass index.
Although a higher BMI is a recognised risk factor for ER+
disease, larger breasts are not always associated with a
high BMI; higher breast weight could be found in a nor-
mal or low BMI postmenopausal women.
Secondly the family and HRT histories were not included
in the analysis. Thirdly, the weight of the formatin-fixed
mastectomy specimen was measured rather than the
weight of the fresh specimen. However this applies to all
specimens and is therefore unlikely to alter our findings.
Finally we used the age of 50 years rather than the date of
the last menstrual period to define the menopausal status.
These limitations could be tackled in a larger prospective
study.
In summary, in women aged 50 years or older with breast
cancer, a higher breast weight seems to be significantly
associated with ER+ disease. If this is confirmed in larger
prospective studies, our findings may have implications
regarding breast cancer prevention with anti-estrogens.
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